Silence Therapeutics (SLN) Other Non Operating Income (2024 - 2026)

Silence Therapeutics has reported Other Non Operating Income for 3 years, with the latest figure at -$482000.0 in Q1 2026.

• Quarterly Other Non Operating Income rose 87.21% year-over-year to -$482000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 84.58% YoY) and the FY2025 annual result came in at $3.5 million, down 22.18% from the prior year.
• Other Non Operating Income eased to -$482000.0 in Q1 2026 per SLN's latest filing, from $880000.0 in the prior quarter.
• Over five years, Other Non Operating Income peaked at $15.7 million in Q4 2024 and troughed at -$3.8 million in Q1 2025.
• A 3-year average of $1.8 million and a median of $770000.0 in 2025 frame the typical range for Other Non Operating Income.
• The widest YoY moves for Other Non Operating Income: up 487.84% in 2025, down 665.07% in 2025.
• Over 3 years, Other Non Operating Income stood at $15.7 million in 2024, then sank by 94.41% to $880000.0 in 2025, then plunged by 154.77% to -$482000.0 in 2026.
• According to Business Quant data, Other Non Operating Income over the past three periods registered -$482000.0, $880000.0, and $770000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.